Clinical trials: Restless Leg Syndrome
- Condition Restless Leg Syndrome
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Restless Legs Syndrome
Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine
This double-blind study will evaluate the pharmacokinetics of a single dose of morphine or gabapentin derived from gabapentin enacarbil (GEn) after administration of morphine and GEn alone and in combination as well as the…
- Trial name
- NCT01476124
- Testing
- GEn 600 mg, Morphine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers
This will be a randomized, double-blind, placebo- controlled cross-over study to investigate the effect of GEn on cardiac repolarisation parameters compared with placebo and a positive control, moxifloxacin.
- Trial name
- NCT01516372
- Testing
- GEn 1200mg, Gen 6000 mg, Moxifloxacin
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome, Multiple Sclerosis
Hypnosis and Direct Autonomic Experience Influence on Chronic Symptoms
Study will look at a limited number of participants with various chronic symptoms. Investigating a new and novel form of hypnosis application called "Direct Autonomic Experience (DAX)" which is using combination of visualization…
- Conditions
- Restless Legs Syndrome, Multiple Sclerosis, Trauma, Psychological, Chronic Disease
- Trial name
- HDAX1 (NCT04303143)
- Testing
- Self-Hypnosis, Direct Autonomic Experience Control
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Inner Group Inc.
Parkinson's Disease, Restless Leg Syndrome
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole Tablets, 0.25 mg to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fasting conditions using a single-dose, randomized, 2-treatment…
- Trial name
- NCT00673088
- Testing
- Ropinirole Hydrochloride
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Parkinson's Disease, Restless Leg Syndrome
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole tablets,0.25 mg, to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fed conditions using a single dose, randomized, 2-treatment…
- Trial name
- NCT00674310
- Testing
- Ropinirole Hydrochloride
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Restless Legs Syndrome (RLS)
Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects
This is a double-blind, placebo-and active-controlled 3-period crossover study designed to assess the effect of GEn 600 mg on simulated driving performance in healthy volunteers.
- Trial name
- NCT01411124
- Testing
- gabapentin enacarbil, diphenhydramine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- XenoPort, Inc.
Apnea, Restless Legs Syndrome
Validation Study for an Unobtrusive Online Sleep Measurement System
The purpose of the study is to determine the precision of an unobtrusive sleep measurement system. The system measures a force sensor signal under the mattress and analyzes sleep quality.
- Conditions
- Apnea, Restless Legs Syndrome, Sleep Fragmentation
- Trial name
- NCT01633151
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Beddit.com Ltd
Restless Legs Syndrome
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.
- Trial name
- NCT00422994
- Testing
- ropinirole dosing for up to 28 days
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline